Typhoid Vaccines Market Segmentation Detailed Study with Forecast to 2025

0
93

Typhoid is a bacterial infection that can lead to diarrhea, high fever, and vomiting. It can be fatal if not treated properly. It is caused by the bacterium Salmonella typhi. The disease is more prevalent in low-income countries, as basic prevention strategies such as good hygiene practices and access to clean water are not available in these countries. However, the spread of the disease in low-income countries is preventable. Every year, around 5,700 cases are reported only in the U.S., out of which 75% occur while traveling overseas. Globally, around 21.5 million people contract typhoid every year. Typhoid can be treated with antibiotics. However, vaccination is more effective for eradicating typhoid, as typhoid vaccines is beneficial in two ways, one by providing protection to vaccinated individual and two, by providing herd immunity indirectly to unvaccinated individuals when the vaccination is carried out on a large scale.

Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37556

The global typhoid vaccines market can be segmented in terms of product, mode of administration, distribution channel, and end-user. In terms of product, typhoid vaccines are of four types viz. Ty21a, Vi capsular polysaccharide vaccine, Vi Conjugate (Vi-TT), and Vi Conjugate (Vi-REPA). Ty21a is a live vaccine and Vi capsular polysaccharide is a sub-unit vaccine. The other two types are restricted to the private sector and they do not have global acceptance. For instance, Vi Conjugate (Vi-TT) is licensed only for the market in India. Based on mode of administration, the typhoid vaccines market can be segmented into oral or injectable. For instance, Ty21a is taken orally, while Vi capsular polysaccharide vaccine is injectable. Based on distribution channel, the typhoid vaccines market can be classified into hospitals, pharmacies, and clinics / health care centers associated with government programs. The inflow of patients to hospitals is expected to increase during the forecast period, as hospitals are considered to be more reliable and they have a large number of suppliers, reimbursement authority, and government support. Based on end-user, the typhoid vaccines market has been segmented into pediatrics and adults.

The typhoid vaccines market is driven by several factors such as increasing government initiatives, rising prevalence of typhoid, growing immunization campaigns across the globe, rising initiatives by non-government organizations for vaccination, and increasing investments by companies in vaccine development. Increased research on typhoid vaccine in the emerging market have opened an array of growth opportunities for the typhoid vaccines market. However, less availability of typhoid vaccines in remote areas and strict regulatory measures are expected to restrain the market from 2017 to 2025.

View Report @ https://www.transparencymarketresearch.com/typhoid-vaccines-market.html

Leave a Reply